Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry

Leukemia Research

Volumn 38, Issue 2, 2014, Pages 149-154

  Lyons, Roger M ^a,b   Marek, Billie J ^b,c   Paley, Carole ^d   Esposito, Jason ^d   Garbo, Lawrence ^b,e   DiBella, Nicholas ^b,f   Garcia Manero, Guillermo ^g  

^a Cancer Care Centers of South Texas   (United States)

^b US Oncology   (United States)

^c TEXAS ONCOLOGY   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e New York Oncology Hematology   (United States)

^f ROCKY MOUNTAIN CANCER CENTERS   (United States)

^g UNIVERSITY OF TEXAS   (United States)

Author keywords

Chelation; Ferritin; Iron overload; Leukemia; Myelodysplastic syndrome; Survival

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DEFERASIROX; DEFEROXAMINE; ERYTHROPOIETIN; FERRITIN; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; HYDROXYUREA; IMMUNOMODULATING AGENT; LENALIDOMIDE; THALIDOMIDE; IRON CHELATING AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CHELATION THERAPY; CLINICAL EVALUATION; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE COURSE; DISEASE FREE SURVIVAL; DISEASE REGISTRY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FERRITIN BLOOD LEVEL; HEART ARRHYTHMIA; HUMAN; INFECTION; IRON CHELATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT DURATION; UNITED STATES; CLINICAL TRIAL; COMPARATIVE STUDY; MIDDLE AGED; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROMES; PROSPECTIVE STUDY; REGISTER; RISK; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CHELATION THERAPY; FEMALE; HUMANS; IRON CHELATING AGENTS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROSPECTIVE STUDIES; REGISTRIES; RISK; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84892543077     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.11.004     Document Type: Article

References (13)

1. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
2. Greenberg P.L., Attar E., Bennett J.M., Bloomfield C.D., De Castro C.M., Deeg H.J., et al. NCCN clinical practice guidelines in oncology: myelodysplastic syndromes. J Natl Compr Canc Netw 2011, 9:30-56.
3. Malcovati L., Porta M.G., Pascutto C., Invernizzi R., Boni M., Travaglino E., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005, 23:7594-7603.
4. Cermak J., Kacirkova P., Mikulenkova D., Michalova K. Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts. Leuk Res 2009, 33:1469-1474.
5. Takatoku M., Uchiyama T., Okamoto S., Kanakura Y., Sawada K., Tomonaga M., et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol 2007, 78:487-494.
6. Rose C., Brechignac S., Vassilief D., Pascal L., Stamatoullas A., Guerci A., et al. GFM (Groupe Francophone des Myélodysplasies) Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies). Leuk Res 2010, 34:864-870.
7. Gattermann N., Finelli C., Porta M.D., Fenaux P., Ganser A., Guerci-Bresler A., et al. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res 2010, 34:1143-1150.
8. List A.F., Baer M.R., Steensma D.P., Raza A., Esposito J., Martinez-Lopez N., et al. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. J Clin Oncol 2012, 30:2134-2139.
9. National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology: myelodysplastic syndromes. Version 1 2012, http://www.nccn.org.
10. Breccia M., Federico V., Loglisci G., Salaroli A., Serrao A., Alimena G. Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes. Haematologica 2011, 96:e41-e42.
11. Della Porta M.G., Malcovati L., Strupp C., Ambaglio I., Kuendgen A., Zipperer E., et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica 2011, 96:441-449.
12. Raptis A., Duh M.S., Wang S.T., Dial E., Fanourgiakis I., Fortner B., et al. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices. Transfusion 2010, 50:190-199.
13. Greenberg P.L., Koller C.A., Cabantchik Z.I., Warsi G., Glynos T., Paley C., et al. Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. Leuk Res 2010, 34:1560-1565.